The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202.
 
Aarti K. Bhatia
Honoraria - ASCO; Clinical Care Options
Consulting or Advisory Role - Merck; Sanofi/Regeneron
Research Funding - Boehringer Ingelheim
 
Yael Flamand
No Relationships to Disclose
 
Jennifer Maria Johnson
Consulting or Advisory Role - Bistol-Myers Squibb; Foundation Medicine; Rakuten Medical
Research Funding - AstraZeneca; Bristol-Myers Squibb; Merck
(OPTIONAL) Uncompensated Relationships - Taproot Health Inc
 
Jeffrey Joseph Ishizuka
Stock and Other Ownership Interests - Jounce Therapeutics; Kronos Bio
Consulting or Advisory Role - Danger Bio; Phenomic AI; Rheos Medicines; Tango Therapeutics; Two River Group
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - I am an inventor on a patent on approaches targeting dsRNA sensing titled: "MODULATING dsRNA EDITING, SENSING, AND METABOLISM TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY AND/OR MODULATORS OF INTRATUMORAL INTERFERON".
 
Fenghai Duan
No Relationships to Disclose
 
Mei Tang
No Relationships to Disclose
 
Vidhya Karivedu
No Relationships to Disclose
 
Rathan M. Subramaniam
Research Funding - Endocyte (Inst)
 
Barbara Burtness
Consulting or Advisory Role - ALX Oncology; CUE Biopharma; Debiopharm Group; Exelixis; Genentech/Roche; IO Biotech; Ipsen; Kura Oncology; Macrogenics; Maverick Therapeutics; Merck; Merck KGaA; Nanobiotix; PPD Global; Rakuten Medical
Speakers' Bureau - Clinical Education Alliance; Oncology Education
Research Funding - AstraZeneca; CUE Biopharma (Inst); Eisai; Exelixis (Inst); Genentech; Kura Oncology; Merck; Merck (Inst); Nektar; Rakuten Medical
Travel, Accommodations, Expenses - Debiopharm Group; Merck